Answers are grounded in this paper and cite their sources.
This study investigates airflow and aerosol deposition in a pediatric mouth-throat (MT) airway model by integrating a cystic fibrosis (CF) inhalation profile, pressurized metered-dose inhaler (pMDI) actuation timing, and an artificial mucus layer to improve understanding of aerosol drug delivery mechanisms. A computed tomography-derived pediatric MT airway model was three-dimensionally printed and coated with artificial pulmonary mucus, establishing a physiologically relevant baseline to assess the effects of a non-Newtonian, shear-thinning mucus layer on drug deposition. The geometry was subsequently integrated into a Next Generation Impactor (NGI) for experimental validation of the computational fluid dynamics framework. The Eulerian wall film (EWF) approach was employed to model the mucus layer, while large-eddy simulation (LES) and discrete-phase modeling (DPM) were used to analyze airflow and particle transport, respectively. Results indicate that inhalation flow rate is the primary determinant of deposition efficiency, with Morris sensitivity analysis showing a strong correlation (rₛ = 0.81). Higher inhalation flow rates increased wall shear stress, thereby enhancing shear-driven particle transport. The presence of shear-thinning mucus modified flow structures by altering secondary flow patterns, inducing asymmetric swirling, and increasing the minimum particle size exiting the trachea by 60.2% (from 0.491 to 0.789 µm) compared with Newtonian mucus. Actuation timing also played a secondary influence on regional deposition, with synchronized pMDI actuation achieving the highest delivery efficiency (approximately 46%) due to improved aerosol entrainment during the acceleration phase of the CF inhalation profile.
No takes yet. Share an insight, caveat, or question.
Dastoorian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: